CABA Cabaletta Bio, Inc.

1.970USD-2.48%Mkt Cap: 334.00M $P/E: —

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabt…

Key Statistics

Company
Market Cap334.00M USD
Enterprise Value143.09M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-167.86M USD
Revenue/Share—
Last Price1.970 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees154
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.70
PEG—
EV/EBITDA-0.78
EV/Revenue—
P/S—
P/B1.61
EPS (TTM)-1.47
EPS (Forward)-1.19
52W Range
1.8306% of range4.230
52W High4.230 USD
52W Low1.830 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-149.80%
ROA-101.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-131.08M USD
CapEx (TTM)1.23M USD
FCF Margin—
FCF Yield-29.44%
Net Debt-199.39M USD
Net Debt/EBITDA1.08
Balance Sheet
Debt/Equity0.24
Current Ratio5.79
Quick Ratio5.64
Book Value/Sh1.26 USD
Cash/Share1.33 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)13.25 USD
Upside (mean)+572.6%
Target Range3.000 USD – 30.00 USD
3.000+572.6% to mean30.00
# Analysts8
Ownership
Shares Out.169.55M
Float141.48M
Insiders0.97%
Institutions94.42%
Short Interest
Short Ratio5.8d
Short % Float21.67%
Short % Out.19.66%
Shares Short33.33M
Short (prev mo.)42.80M
Technical
SMA 502.747 (-28.3%)
SMA 2002.911 (-32.3%)
Beta3.48
S&P 52W Chg16.45%
Avg Vol (30d)5.95M
Avg Vol (10d)6.00M
Technical Indicators
RSI (14)32.7
MACD-0.2562
MACD Signal-0.2333
MACD Hist.-0.0229
BB Upper3.162 USD
BB Middle2.349 USD
BB Lower1.535 USD
BB Width69.27%
ATR (14)0.1834 USD
Vol Ratio (20d)0.35x